Virological phenotype switches under salvage therapy with lopinavir-ritonavir in heavily pretreated HIV-1 vertically infected children

AIDS

Volumn 18, Issue 2, 2004, Pages 247-255

  Galán, Isabel ^a   Jiménez, José L ^a   González Rivera, Milagros ^a   De José, Ma Isabel ^b   Navarro, Ma Luisa ^a   Ramos, José T ^c   Mellado, Ma José ^b   Gurbindo, Ma Dolores ^a   Bellón, José Ma ^a   Resino, Salvador ^a   Cabrero, Esther ^d   Muñoz Fernández, Ma Angeles ^a  

^a HOSPITAL GENERAL UNIVERSITARIO GREGORIO MARAÑÓN   (Spain)

^b HOSPITAL UNIVERSITARIO LA PAZ   (Spain)

^c HOSPITAL UNIVERSITARIO 12 DE OCTUBRE   (Spain)

^d Abbot Laboratorios   (Spain)

Author keywords

Antiretroviral therapy; Biological clones; Children; HIV 1; Viral phenotype

Indexed keywords

ABACAVIR; ANTIRETROVIRUS AGENT; CD4 ANTIGEN; DIDANOSINE; EFAVIRENZ; INDINAVIR; LAMIVUDINE; LOPINAVIR; NELFINAVIR; NEVIRAPINE; RITONAVIR; SAQUINAVIR; STAVUDINE;

ARTICLE; CLINICAL ARTICLE; CLINICAL TRIAL; COCULTURE; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DERIVATIZATION; DRUG EFFECT; FEMALE; FOLLOW UP; HEALTH STATUS; HUMAN; HUMAN CELL; HUMAN IMMUNODEFICIENCY VIRUS 1; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; INFANT; MALE; MOLECULAR CLONING; NONHUMAN; PERIPHERAL BLOOD MONONUCLEAR CELL; PHENOTYPE; PRESCHOOL CHILD; PRIORITY JOURNAL; SYNCYTIUM; T LYMPHOCYTE; VERTICAL TRANSMISSION; VIRUS ISOLATION; VIRUS LOAD; VIRUS STRAIN;

DISEASE TRANSMISSION, VERTICAL; DRUG COMBINATIONS; FEMALE; HIV INFECTIONS; HIV PROTEASE INHIBITORS; HIV-1; HUMANS; INFANT; LEUKOCYTES, MONONUCLEAR; MALE; PHENOTYPE; PYRIMIDINONES; RITONAVIR; SALVAGE THERAPY; T-LYMPHOCYTE SUBSETS; VIRAL LOAD; VIRUS REPLICATION;

EID: 10744219648     PISSN: 02699370     EISSN: None     Source Type: Journal    
DOI: 10.1097/00002030-200401230-00014     Document Type: Article

References (34)

1. Koot M, Vos AH, Keet RP, de Goede RE, Dercksen MW, Terpstra FG, et al. HIV-1 biological phenotype in long-term infected individuals evaluated with an MT-2 cocultivation assay. AIDS 1992, 6:49-54.
2. Alkhatib G, Combadiere C, Broder C, Feng Y, Kennedy PE, Murphy PM, Berger EA. CC CKR5: A RANTES, MIP-1a, MIP-1b receptor as a fusion cofactor for macrophage-tropic HIV-1. Science 1996, 272:1955-1958.
3. Fenyo EM, Albert J, Asjo B. Replicative capacity, cytopathic effect and cell tropism of HIV. AIDS 1989, 3:S5-S12.
4. Feng Y, Broder CC, Kennedy PE, Berger EA. HIV-1 entry cofactor: functional cDNA cloning of a seven-transmembrane, G protein-coupled receptor. Science 1996, 272:872-877.
5. Simmons G, Clapham PR, Picard L, Offord RE, Rosenkilde MM, Schwartz TW, et al. Potent inhibition of HIV-1 infectivity in macrophages and lymphocytes by a novel CCR5 antagonist. Science 1997, 276:276-279.
6. Zaitseva MB, Lee S, Rabin RL, Tiffany HL, Farber JM, Peden KW, et al. CXCR4 and CCR5 on human thymocytes: biological function and role in HIV-1 infection. J Immunol 1998, 161:3103-3113.
7. Fauci AS, Pantaleo G, Stanley S, Weissman D. Immunopathogenic mechanisms of HIV infection. Ann Intern Med 1996, 124:654-663.
8. Koot M, van 't Wout AB, Kootstra NA, de Goede RE, Tersmette M, Schuitemaker H. Relation between changes in cellular load, evolution of viral phenotype, and the clonal composition of virus populations in the course of human immunodeficiency virus type 1 infection. J Infect Dis 1996, 173:349-354.
9. Koot M, van Leeuwen R, de Goede RE, Keet IP, Danner S, Eeftinck Schattenkerk JK, et al. Conversion rate towards a syncytium-inducing (SI) phenotype during different stages of human immunodeficiency virus type 1 infection and prognostic value of SI phenotype for survival after AIDS diagnosis. J Infect Dis 1999, 179:254-258.
10. Kupfer B, Kaiser R, Rockstroh JK, Matz B, Schneweis KE. Role of HIV-1 phenotype in viral pathogenesis and its relation to viral load and CD4+ T-cell count. J Med Virol 1998, 56:259-263.
11. Rodrigo AG. Dynamics of syncytium-inducing and non-syncytium-inducing type 1 human immunodeficiency viruses during primary infection. AIDS Res Hum Retroviruses 1997, 13:1447-1451.
12. Correa R, Muñoz-Fernández MA. Viral phenotype affects the thymical production of new T-cells in HIV-1 infected children. AIDS 2001, 15:1959-1963.
13. Palella FJ, Jr., Delaney KM, Moorman AC, Loveless MO, Fuhrer J, Satten GA, et al. Declining morbidity and mortality among patients with advanced human immunodeficiency virus infection. HIV Outpatient Study Investigators. N Engl J Med 1998, 338:853-860.
14. Purswani M, Johann-Liang R, Cervia J, Noel GJ. Effect of changing antiretroviral therapy on human immunodeficiency virus viral load: experience with fifty-four perinatally infected children. Pediatr Infect Dis J 1999, 18:512-516.
15. Rutstein RM, Feingold A, Meislich D, Word B, Rudy B. Protease inhibitor therapy in children with perinatally acquired HIV infection. AIDS 1997, 11:F107-F111.
16. Deeks SG, Barbour JD, Martin JN, Swanson MS, Grant RM. Sustained CD4+ T cell response after virologic failure of protease inhibitor-based regimens in patients with human immunodeficiency virus infection. J Infect Dis 2000, 181:946-953.
17. Grabar S, Le Moing V, Goujard C, Leport C, Kazatchkine MD, Costagliola D, et al. Clinical outcome of patients with HIV-1 infection according to immunologic and virologic response after 6 months of highly active antiretroviral therapy. Ann Intern Med 2000, 133:401-410.
18. Resino S, Bellon JM, Sanchez-Ramon S, Gurbindo D, Ruiz-Contreras J, Leon JA, et al. Impact of antiretroviral protocols on dynamics of AIDS progression markers. Arch Dis Child 2002, 86:119-124.
19. Resino S, Correa R, Bellon J, Sanchez-Ramon S, Muñoz-Fernandez M. Characterizing Immune Reconstitution after Long-Term HAART in Pediatric AIDS. AIDS Res Hum Retrovirses 2002, 18:1395-1406.
20. Resino S, Sanchez-Ramon S, Bellon JM, Correa R, Abad ML, Munoz-Fernandez MA. Immunological recovery after 3 years' antiretroviral therapy in HIV-1- infected children. AIDS 2002, 16:483-486.
21. Sleasman JW, Nelson RP, Goodenow MM, Wilfret D, Hutson A, Baseler M, et al. Immunoreconstitution after ritonavir therapy in children with human immunodeficiency virus infection involves multiple lymphocyte lineages. J Pediatr 1999, 134:597-606.
22. Van Rossum AM, Niesters HG, Geelen SP, Scherpbier HJ, Hartwig NG, Weemaes CM, et al. Clinical and virologic response to combination treatment with indinavir, zidovudine, and lamivudine in children with human immunodeficiency virus-1 infection: a multicenter study in the Netherlands. On behalf of the Dutch Study Group for Children with HIV-1 infections. J Pediatr 2000, 136:780-788.
23. Cvetkovic R, Goa K. Lopinavir/ritonavir : a review of its use in the management of HIV infection. Drugs 2003, 63:769-802.
24. Munoz-Fernandez MA, Obregon E, Navarro J, Borner C, Gurbindo MD, Sampelayo TH, et al. Relationship of virologic, immunologic, and clinical parameters in infants with vertically acquired human immunodeficiency virus type 1 infection. Pediatr Res 1996, 40:597-602.
25. Schuitemaker H, Koot M, Kootstra NA, Dercksen MW, de Goede RE, van Steenwijk RP, et al. Biological phenotype of human immunodeficiency virus type 1 clones at different stages of infection: progression of disease is associated with a shift from monocytotropic to T-cell-tropic virus population. J Virol 1992, 66:1354-1360.
26. Strijbosch LW, Buurman WA, Does RJ, Zinken PH, Groenewegen G. Limiting dilution assays. Experimental design and statistical analysis. J Imunol Methods 1987, 97:133-140.
27. Tersmette M, de Goede RE, Al BJ, Winkel IN, Gruters RA, Cuypers HT, et al. Differential syncytium-inducing capacity of human immunodeficiency virus isolates: frequent detection of syncytium-inducing isolates in patients with acquired immunodeficiency syndrome (AIDS) and AIDS-related complex. J Virol 1988, 62:2026-2032.
28. Resino S, Navarro J, Bellón JM, Gurbindo D, León JA, Muñoz-Fernández MA. Naïve and memory CD4+ T-cells and T-cell activation markers in HIV-1 infected children on HAART. Clin Exp Immunol 2001, 125:266-273.
29. Najera I, Holguin A, Quinones-Mateu ME, Munoz-Fernandez MA, Najera R, Lopez-Galindez C, et al. Pol gene quasispecies of human immunodeficiency virus: mutations associated with drug resistance in virus from patients undergoing no drug therapy. J Virol 1995, 69:23-31.
30. van't Wout AB, Ran LJ, de Jong MD, Bakker M, van Leeuwen R, Notermans DW, et al. Selective inhibition of syncytium-inducing and nonsyncytium-inducing HIV-1 variants in individuals receiving didanosine or zidovudine, respectively. J Clin Invest 1997, 100:2325-2332.
31. van 't Wout AB, Ran LJ, Nijhuis M, Tijnagel JM, de Groot T, van Leeuwen R, et al. Efficient inhibition of both syncytium-inducing and non-syncytium- inducing wild-type HIV-1 by lamivudine in vivo. AIDS 1998, 12:1169-1176.
32. Shirasaka T, Chokekijchai S, Yamada A, Gosselin G, Imbach JL, Mitsuya H. Comparative analysis of anti-human immunodeficiency virus type 1 activities of dideoxynucleoside analogs in resting and activated peripheral blood mononuclear cells. Antimicrob Agents Chemother 1995, 39:2555-2559.
33. Fauci AS. Host factors and the pathogenesis of HIV-induced disease. Nature 1996, 384:529-534.
34. Pedroza-Martins L, Boscardin WJ, Anisman-Posner DJ, Schols D, Bryson YJ, Uittenbogaart CH. Impact of cytokines on replication in the thymus of primary human immunodeficiency virus type 1 isolates from infants. J Virol 2002, 76:6929-6943.